DrugPatentWatch Database Preview
Certolizumab pegol - Biologic Drug Details
» See Plans and Pricing
Summary for certolizumab pegol
Tradenames: | 1 |
Patents: | 87 |
Applicants: | 1 |
BLAs: | 1 |
Suppliers: see list | 1 |
Recent Clinical Trials: | See clinical trials for certolizumab pegol |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for certolizumab pegol |
Recent Clinical Trials for certolizumab pegol
Identify potential brand extensions & biosimilar entrants
Sponsor | Phase |
---|---|
UCB Biopharma SRL | Phase 3 |
RenJi Hospital | N/A |
UCB Biopharma S.P.R.L. | Phase 1 |
Recent Litigation for certolizumab pegol
Identify key patents and potential future biosimilar entrants
PTAB Litigation
Petitioner | Date |
---|---|
2017-12-20 |
Pharmacology for certolizumab pegol
Mechanism of Action | Tumor Necrosis Factor Receptor Blocking Activity |
Patent Text Search: US Patents for certolizumab pegol
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Ucb Inc | CIMZIA | certolizumab pegol | INJECTABLE; INJECTION | 125160 | 001 | 2008-04-22 | Start Trial | Medarex, Inc. (Princeton, NJ) | 2025-11-08 | RX | search | |
Ucb Inc | CIMZIA | certolizumab pegol | INJECTABLE; INJECTION | 125160 | 001 | 2008-04-22 | Start Trial | Tobinick; Edward Lewis (Los Angeles, CA) | 2019-02-24 | RX | search | |
Ucb Inc | CIMZIA | certolizumab pegol | INJECTABLE; INJECTION | 125160 | 001 | 2008-04-22 | Start Trial | Stowers Institute for Medical Research (Kansas City, MO) | 2026-04-03 | RX | search | |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for certolizumab pegol
Country | Patent Number | Estimated Expiration |
---|---|---|
World Intellectual Property Organization (WIPO) | 2016140922 | Start Trial |
Japan | 5608914 | Start Trial |
European Patent Office | 1720996 | Start Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for certolizumab pegol
Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|
2020 00011 | Denmark | Start Trial | PRODUCT NAME: UPADACITINIB; REG. NO/DATE: EU/1/19/1404 20191218 |
20C/505 | Belgium | Start Trial | PRODUCT NAME: UPADACITINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: EU/1/19/1404 20191218 |
2020000000022 | Italy | Start Trial | PRODUCT NAME: UPADACITINIB IN QUALSIASI FORMA PROTETTA DAL BREVETTO DI BASE(RINVOQ); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/19/1404, 20191218 |
>Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |